A few days ago, at the Chinese Medicine Industry Information Conference of the China Association of Chinese Medicines, the 2021 TOP100 of proprietary Chinese medicine enterprises was officially released, and Good Doctor Group was listed on the list, ranking 37th.
Courtesy of the picture
It is reported that the entry threshold of the listed enterprises reached 740 million yuan, an increase of 290 million over 2020. Among them, there are 10 enterprises with more than 10 billion yuan, an increase of 5 over the previous year, 75 production enterprises between 1 billion and 10 billion yuan, an increase of 14 over the same period of the previous year, and 15 shortlisted enterprises with less than 1 billion, a decrease of 19 over the same period of the previous year, indicating that the number of enterprises with core competitiveness in the Traditional Chinese medicine industry is growing year by year.
At the same time, the "2021 Clinical Value Chinese Patent Medicine Brand List" was also released at the meeting, and the core product rehabilitation new liquid produced by Sichuan Good Doctor Panxi Pharmaceutical Co., Ltd., a subsidiary company of Good Doctor Group, was on the list.
It is understood that the brand list is mainly based on the "General Rules for the Evaluation of Chinese Medicine Brands", "Evaluation of Chinese Proprietary Chinese Medicines", "Evaluation of Chinese Proprietary Chinese Medicines" and "Evaluation of Chinese Medicine Brands" issued by the China Association of Chinese Medicines, and the evaluation basis and selection principles for the evaluation of Chinese medicine tablets, and a total of 138 proprietary Chinese medicine products have been shortlisted. It covers 20 advantageous disease areas of encephalopathy, cardiovascular, respiratory, tonic, spleen and stomach, hepatobiliary, tumor, nephropathy, endocrinology, andrology, orthopedics, rheumatism and immunology, skin, anorectum, urology, surgery, gynecology, pediatrics, otorhinolaryngology, ophthalmology, including more than 10 dosage forms such as capsules, pills, granules, tablets, aerosols, patches and injections. The successful entry of Good Doctor Rehabilitation New Liquid highlights the great clinical value of Good Doctor Rehabilitation's new series of drugs.
Good Doctor Rehabilitation New Liquid has a good reputation among doctors and patient groups. Listed for more than 20 years, has been recognized and prescribed by more than 4,000 second-class and above hospitals and tens of thousands of clinical experts across the country, has become a standing drug for 100,000 primary medical units, trusted by the majority of patients, and has also obtained the natural medicine product license issued by Health Canada with high standards, becoming the only successfully registered wound repair Chinese medicine variety in Canada.
Good Doctor Group has now spanned 35 years of development, the company has always put innovation as a support for improving productivity and comprehensive strength in the core position of the overall development of enterprises, over the years is committed to innovative drug research and development, high-quality drug manufacturing, precision medical services and big health management, to provide the public with perfect medical and health industry chain services. Taking innovation as a breakthrough, while adhering to the essence of the industry and demanding the quality of details, Good Doctor Group has worked products and services to establish a new liquid for good doctor rehabilitation, good doctor children's anti-sensory granules, good doctor pediatric solution granules, good doctor mulberry ginger cold tablets, the peak of medical curiosity resistance, the combination of medical qi strong and strong, good doctor clam green series, Qing palace classic chinese medicine series and other brand drugs, as well as rehabilitation Xin toothpaste, red pomegranate mask and other big health products, and established a significant competitive advantage. In 2020, the Group continued to exert efforts, increaseD investment, continuously adjust the product structure, and further expand the product line, and newly listed products such as bone pain tincture, Danguo Women's Health Decoction Paste, and Azelastine Hydrochloride Nasal Spray.
Good Doctor said that the continuous implementation of the innovation-driven development strategy, the group has shown a strong explosive force and sustainable development ability, and the brand influence of "Good Doctor" has also been continuously improved. In the future, Good Doctor Group will take the "Healthy China 2030" national strategy as the guide, seize new opportunities for industrial development, promote the high-quality development of the Chinese medicine industry with scientific and technological innovation, and contribute to the construction of a strong country in traditional Chinese medicine.